Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 diabetes, and cardiovascular treatments.
read more Read More
Posted inBusiness & Finance
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 diabetes, and cardiovascular treatments.
read more Read More